June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Overall Ocular Discomfort Score as a Symptom of Meibomian Gland Dysfunction Severity
Author Affiliations & Notes
  • Layla Ajouz
    AbbVie Inc, California, United States
  • Ashley Nguyen
    AbbVie Inc, California, United States
  • Cathy Zhao
    AbbVie Inc, California, United States
  • Michael R Robinson
    AbbVie Inc, California, United States
  • Footnotes
    Commercial Relationships   Layla Ajouz AbbVie, Code C (Consultant/Contractor); Ashley Nguyen AbbVie, Code E (Employment); Cathy Zhao AbbVie, Code E (Employment); Michael Robinson AbbVie, Code E (Employment)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4002. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Layla Ajouz, Ashley Nguyen, Cathy Zhao, Michael R Robinson; Overall Ocular Discomfort Score as a Symptom of Meibomian Gland Dysfunction Severity. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4002.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Dry Eye Disease (DED) is characterized by two main types: aqueous deficiency and evaporative tear loss. Evaporative tear loss is frequently associated with Meibomian Gland Dysfunction (MGD). Given the importance of evaluating symptoms for regulatory approval, a clinical trial was performed to characterize MGD severity and identify clinical endpoints that can be potentially used for drug registrational purposes to treat MGD.

Methods : This prospective, multicenter, non-interventional study enrolled three cohorts based on standardized criteria: subjects without MGD, mild-to-moderate MGD, and severe MGD. The Subject Ocular Symptom Questionnaire (SOSQ) assessed blurred vision, burning, dryness, pain, light sensitivity, itching, and foreign body sensation as well as overall ocular discomfort over the last 7 days. Patient responses were assessed on a 5-point severity scale from 0 (none) to 4 (very severe). Inter-item correlation analysis (arithmetic means) was calculated to provide a global estimate of symptom correlation of Overall Ocular Discomfort with the other 7 ocular symptoms representative of MGD. The repeatability of the Overall Ocular Discomfort item was examined using test-retest reliability methods and weighted Kappa (Κw) statistics with 95% confidence intervals (CI).

Results : 70 subjects were enrolled across 3 cohorts with a Tear Break Up Time (TBUT) <10 seconds. The correlation of Overall Ocular Discomfort with other ocular symptoms ranged from moderately strong to strong (0.684 to 0.844). Additionally, the average of the inter-item correlations suggests that Overall Ocular Discomfort demonstrated moderately strong global correlations with all 7 symptoms (r2=0.777). Overall Ocular Discomfort demonstrated acceptable reproducibility, with calculated Kw coefficients of 0.66.

Conclusions : MGD and DED has a significant impact on ocular symptoms and vision related activities. The correlation of Overall Ocular Discomfort with other ocular symptoms was strong throughout the study. The findings from this observational study can help inform endpoints and PRO development for future clinical trials in patients with MGD and DED.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×